Cargando…
Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma
There is no useful biomarker to evaluate treatment response and early relapse in head and neck squamous cell carcinoma (HNSCC). Circulating tumor DNA (ctDNA) is a promising biomarker for detecting minimal residual diseases and monitoring treatment effect. We investigated whether individualized ctDNA...
Autores principales: | Kogo, Ryunosuke, Manako, Tomomi, Iwaya, Takeshi, Nishizuka, Satoshi, Hiraki, Hayato, Sasaki, Yasushi, Idogawa, Masashi, Tokino, Takashi, Koide, Ayaka, Komune, Noritaka, Yasumatsu, Ryuji, Nakagawa, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636504/ https://www.ncbi.nlm.nih.gov/pubmed/35352507 http://dx.doi.org/10.1002/cam4.4726 |
Ejemplares similares
-
Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
por: Wakasaki, Takahiro, et al.
Publicado: (2020) -
Fledglings in p53 signaling network
por: Tokino, Takashi, et al.
Publicado: (2017) -
Effectiveness and safety of weekly paclitaxel and cetuximab as a salvage chemotherapy following immune checkpoint inhibitors for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter clinical study
por: Wakasaki, Takahiro, et al.
Publicado: (2022) -
Biological and genetic characterization of a newly established human external auditory canal carcinoma cell line, SCEACono2
por: Komune, Noritaka, et al.
Publicado: (2023) -
Corrigendum to “Prognostic Effect of Long Noncoding RNA NEAT1 Expression Depends on p53 Mutation Status in Cancer”
por: Idogawa, Masashi, et al.
Publicado: (2019)